Celcuity Inc. — Form 8-K/A
Filed July 15, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 82/100
What the filing says
Celcuity announced FDA approval of REVTORPYK (gedatolisib) on July 14, 2026, for HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer. In Phase 3 VIKTORIA-1 trial, REVTORPYK+palbociclib+fulvestrant reduced progression/death risk by 76% (median PFS 9.3 vs 2.0 months); REVTORPYK+fulvestrant reduced risk by 67% (median PFS 7.4 vs 2.0 months). Commercial launch planned late Q3 2026; supplemental NDA for PIK3CA-mutant cohort expected Q3 2026.
Why this rating
First FDA-approved pan-PI3K/mTOR inhibitor addresses large unmet need (~42% of ~70% HER2- breast cancers); transforms company from clinical-stage to commercial biotech with revenue potential materially significant to $457.5M market cap.
See more from July 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.